These differentiation defects can be partly attributed to the presence of PMN-MDSCs that secrete high levels of alpha-defensins HNP1-3, which antagonize the purinergic receptor P2RY6 and inhibit AMPK-mediated autophagy in CMML patients [51]. Here, PRKAA2 is linked to chronic myelomonocytic leukemia.